Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Simplex | 1 | 2020 | 93 | 0.650 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 340 | 0.610 |
Why?
|
| Magnesium Sulfate | 1 | 2018 | 18 | 0.590 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2018 | 11 | 0.590 |
Why?
|
| Hospital Mortality | 2 | 2021 | 850 | 0.570 |
Why?
|
| Tuberculosis, Spinal | 1 | 2017 | 7 | 0.560 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2017 | 33 | 0.540 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2017 | 39 | 0.540 |
Why?
|
| Edema | 1 | 2017 | 124 | 0.520 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 156 | 0.520 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 487 | 0.490 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 578 | 0.470 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 2736 | 0.440 |
Why?
|
| Bone Marrow | 1 | 2014 | 270 | 0.420 |
Why?
|
| Hospitalization | 3 | 2021 | 2069 | 0.420 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 129 | 0.410 |
Why?
|
| MicroRNAs | 1 | 2019 | 675 | 0.390 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 592 | 0.390 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1705 | 0.380 |
Why?
|
| Rhode Island | 2 | 2021 | 26 | 0.230 |
Why?
|
| Tachypnea | 1 | 2021 | 4 | 0.190 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2021 | 12 | 0.180 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 26 | 0.170 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 131 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 55 | 0.170 |
Why?
|
| Simplexvirus | 1 | 2020 | 80 | 0.170 |
Why?
|
| Hypotension | 1 | 2021 | 116 | 0.170 |
Why?
|
| Epidemics | 1 | 2021 | 82 | 0.170 |
Why?
|
| Fatal Outcome | 1 | 2020 | 300 | 0.160 |
Why?
|
| Necrosis | 1 | 2020 | 232 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 1 | 2020 | 105 | 0.160 |
Why?
|
| Comorbidity | 2 | 2021 | 1545 | 0.160 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 146 | 0.160 |
Why?
|
| Triage | 1 | 2021 | 205 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 50 | 0.150 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 160 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 140 | 0.150 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2019 | 46 | 0.150 |
Why?
|
| Middle Aged | 6 | 2021 | 31075 | 0.150 |
Why?
|
| Antiviral Agents | 2 | 2021 | 712 | 0.140 |
Why?
|
| Humans | 13 | 2021 | 129212 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 1036 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 79 | 0.130 |
Why?
|
| Back Pain | 1 | 2017 | 51 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 428 | 0.130 |
Why?
|
| Adult | 7 | 2021 | 35464 | 0.130 |
Why?
|
| Aged | 5 | 2021 | 22030 | 0.120 |
Why?
|
| Female | 8 | 2021 | 68600 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3372 | 0.120 |
Why?
|
| Pneumonia | 1 | 2020 | 613 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 670 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 663 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 997 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1181 | 0.100 |
Why?
|
| Male | 6 | 2021 | 63491 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1565 | 0.090 |
Why?
|
| Mutation | 1 | 2019 | 3715 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2021 | 10189 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 7061 | 0.070 |
Why?
|
| Risk Factors | 1 | 2021 | 9747 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2021 | 14488 | 0.070 |
Why?
|
| Pandemics | 2 | 2021 | 1477 | 0.050 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2021 | 34 | 0.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 74 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 92 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2021 | 192 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 264 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 395 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 248 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2021 | 597 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 840 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1121 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 547 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 3791 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 5408 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 7103 | 0.020 |
Why?
|